Zhejiang / Biomedicine and medical devices / Complete systems and use-case applications Company Structure Study

Comparative structure study

The largest recorded industry, Biomedicine, contains 121 records (96.0% of this 126-record cohort). The remaining cohort contains 5 records. The comparison concerns archive composition.

The recorded sub-industry label Advanced medical devices accounts for 30.2% here (38/126), compared with 23.4% in the parent set (321/1,373), an absolute gap of 6.8 percentage points.

27/126 companies link to pages with existing source-supported excerpts (21.4% of the cohort). The other 99 records remain usable for archive composition, but do not support new operating case studies.

An ID-deduplicated archive snapshot, not the whole market, current recognition or operating results.

The parent set, Biomedicine and medical devices / Complete systems and use-case applications, contains 1,373 records. This cohort contributes 126 (9.2%); 1,247 records remain after excluding it.

The parent set, Zhejiang, contains 1,840 records. This cohort contributes 126 (6.8%); 1,714 records remain after excluding it.

Ratio of label participation, not market share; multi-label counts overlap.

Excluding this cohort, the recorded sub-industry label Advanced medical devices covers 283/1,247 remaining records (22.7%), an absolute gap of 7.5 percentage points from this cohort.

The full industry distribution has 3 labels; the top 3 contain 126/126 records (100.0%).These labels cover all records with known labels.

For 126 records with known labels, the effective category count is 1.1, versus 3 actual labels. Definitions and scope are in the methodology.

Record counts do not rank supply capability or economic size.

Non-empty fields are not necessarily accurate or supported by originals.

Counts concern existing reviewed bilingual excerpts, not re-certification of originals or entire reports.

A rule hit prioritises review; it does not establish that the entire field is wrong. One record can trigger several rules.

31 of this cohort’s 126 records link through existing company-ID mappings to 2026 lists from all jurisdictions (24.6%). This intersection measures list linkage, not successful recognition or company growth.

List rows and company IDs are separate counts, not new firms or final recognition.

The 2025 macro context for Zhejiang uses a different denominator from this cohort.

Shared records with Zhejiang / Biomedicine Company Structure Study: 121; records in this cohort but outside that set: 5. The intersection/union ratio is 74.2%, a measure of label overlap rather than business collaboration. Read comparison

Shared records with Biomedicine / Biomedicine and medical devices / Complete systems and use-case applications Supply-chain Study: 121; records in this cohort but outside that set: 5. The intersection/union ratio is 9.3%, a measure of label overlap rather than business collaboration. Read comparison

Stable-ID samples, not rankings; metrics use the full cohort.